



Opportunities for SMEs in IMI2 Call 23

15 June 2020

Today's webinar

Will cover all aspects of the Call topic



- Introduction to IMI programme
- Why SMEs should get involved
- IMI call process & tips on joining an applicant consortium
- IMI call 23 topics
- Other opportunities for SMEs in IMI projects

Will not cover rules and procedures


- A webinar on rules and procedures will take place on **Tuesday 30 June | 11:00 CEST**
- Register at:
attendee.gotowebinar.com/register/8280003561395178765

Why is a partnership in health needed?

Because drug development is still very...



What is the Innovative Medicines Initiative?



IMI is a platform where all involved in drug development can collaborate on shared challenges

Why do we want SMEs in IMI projects?

- SMEs can act as a **key interface** between latest academic discoveries and implementation in industry
- SMEs can bring **industrial grade products/services** to IMI projects
- With a commercial focus, SMEs can **drive projects to achieve** high impact results
- By developing products & services, SMEs can ensure the results of IMI projects are **widely available after the funding ends**
- Help create a **favourable ecosystem for SME innovation and growth.**



Why should an SME participate in an IMI project?

- IMI projects are focused on **translating results from research** into real world outcomes – an opportunity for SMEs
- SMEs can **fine-tune innovative services and products** with the actual end-user scientists
- Collaboration with large pharmaceutical companies and others allows **access to whole value chain** of drug discovery & the **building of research and business networks**
- **Enhancing reputation and visibility.** IMI project achievements often get recognised and promoted on an international level
- Funding: **100%** of costs **reimbursed**



Examples of SMEs from IMI projects

Product Development



- Molecular Affinity Screening System developed within the K4DD project using input from pharma partners.
- Measures target-ligand binding kinetics in high-throughput format

- Acquired by




Product Development



Ebola Ag K-SeT rapid test

- Rapid Ebola diagnostic based on laminar flow developed by Coris, an SME.
- Results available within 15 minutes.
- Final testing in in DRC



Positive for
Ebola antigen

Negative

Business Development



- RADAR-BASE open source IT platform for remote monitoring using smartphone and wearable devices
- Developed in RADAR-CNS project, **now facilitating at least 12 additional studies:**
 - Over 13 500 study participants
 - Over EUR 13 million additional investment.
- Developed by SME [The Hyve](#) & King's College London
- <https://radar-base.org/>

Business Development

- **ITTM** Information Technology for Translational Medicine
- Provides **data curation services** developed in the eTRIKS project
- Currently:
 - > 7 employees
 - > 30 clients (Pharma, biotech, project consortia)
- Certified by the EHDEN project for harmonisation of EHR data
- More information:
- https://www.ittm-solutions.com/images/videos/ITTM-Web_FINAL.mp4

IMI IP rules consider SME's needs

- **Assets protected** – you decide what to bring in to the project
- **New results owned by the generator**
- **Result owner decides** best protection modalities & exploitation strategy

“We are a start-up company and our patents are the most valuable asset that we have. We jumped into the project and we are glad that we did, because our IP rights are protected – participating in this project didn't harm us at all.”



From Idea to Project: IMI2 calls for proposals


Idea to Project: IMI2 Calls for Proposals



Topic Definition

- Industrial partners align themselves around a real challenge for industry and agree to work together **and commit resources**
- **New ideas** from public sector, universities, SMEs etc. are needed to address the challenge
- **Scale** is a key to success and is provided through **IMI funding**
- **Consultation** with H2020 countries, IMI2 SC, EC


Idea to Project: IMI2 Calls for Proposals




Proposal Submission & Evaluation

- **Consortia** applying for the public funding **form** and submit a Short Proposal meeting the requirements of the topic text
- All proposals evaluated by an **independent panel**
- **Only top ranked proposal** goes through to the next stage


Idea to Project: IMI2 Calls for Proposals



Idea to Project: IMI2 Calls for Proposals



Idea to Project: IMI2 Calls for Proposals



Joining an applicant consortium

- **Be proactive**
 - Develop your network
 - Reach out to potential coordinators, make their life easy
- **Be prepared**
 - Summarise your skills and proposed topic activities
 - Estimate the budget required
- **Be flexible**
 - Don't restrict yourself to a single set of activities



Finding consortia / partners

- **Network with your contacts**
- Network with **SME & topic webinar participants**
- **Use Partner Search Tools:**
 - EU Funding & Tenders Portal: <https://europa.eu/!QU87Nx>
 - IMI partnering website: <http://www.imi-partnering.eu>
- Get in touch with your **local IMI contact point:**
www.imi.europa.eu/content/states-representatives-groups



SME participation in IMI2 Call 23

Topic texts & webinars

- Call 23 Launch date: 23 June 2020
- Short Proposal submission date: 29 September 2020
- A summary of all topics is presented below, if interested in a particular topic, please:
 - Read the topic text
www.imi.europa.eu/apply-funding/future-topics
www.imi.europa.eu/apply-funding/open-calls/imi2-call-23
 - View the topic specific webinars at:
www.imi.europa.eu/news-events/events/imi2-call-22-23-webinars

IMI2 Call 23 – Topics

- Returning clinical trial data to study participants within a GDPR compliant and approved framework
- Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance *This topic is part of IMI's Antimicrobial Resistance (AMR) Accelerator programme.*
- A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases
- Optimal treatment for patients with solid tumours in Europe through artificial intelligence
- Shortening the path to rare disease diagnosis by using new born genetic screening and digital technologies
- Behavioural model of factors affecting patient adherence

Topic 1: Returning clinical trial data to study participants within a GDPR compliant and approved framework

The topic aims to:

- Align local and pan-European implementations and best practice for handling personal data protection regulations in order to foster the harmonisation of the legal framework applicable to medical research in the Member States
- Deliver a pan-European prototype process to return clinical trial data to study participants
 - For at least one “real” study, the prototype process should demonstrate within a proof of concept mechanism how relevant clinical trial data can be integrated or interconnected with at least two existing repositories.

Topic 1: Returning clinical trial data

Expected contributions from SMEs

- Legal and data protection areas as well as interoperability of data and framework for their secured exchanges.
- Robust expertise in health and clinical data interoperability and secured exchanges

Duration

48 months

Indicative budget

- In-kind contribution: EUR 4.93 million
- IMI2 JU contribution: up to EUR 3.26 million

Topic 2: Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance

The topic aims to:

- Evaluate the burden of disease of AMR by estimating inpatients' and outpatients' infection rates in at least 8 EU countries
- Build a comprehensive AMR model
- Collecting, gathering, and analysing data
- Develop and test a cost-effectiveness analysis (CEA) of alternative mAbs and vaccines strategies

Topic 2: Monoclonal antibodies and vaccines

Expected contributions from SMEs

- Epidemiology, Statistics, Health Economics
- Database management, Database web programming, Management Information Systems;

Duration

60 months

Indicative budget

- In-kind contribution: EUR 2.76 million
- IMI2 JU contribution: up to EUR 6.50 million



Topic 3: A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases

The topic aims to:

- Agreed a set of principles to enable sharing of data and samples.
- Establish a network that can house high quality data and samples & appropriate governance systems to facilitate sharing
- Test the above with the defined case studies

Topic 3: Accelerating biomarker discovery

Expected contributions from SMEs

- Expertise regarding establishing and managing a harmonised online data portal
- Business, financial, and economics experience to transform the bio-sample repository into a self-sustainable business:

Duration

60 months

Indicative budget

- In-kind contribution: EUR 9.72 million
- IMI2 JU contribution: up to EUR 9.68 million



Topic 4: Optimal treatment for patients with solid tumours in Europe through artificial intelligence

The topic aims to:

- Establish a guideline-based decision support for prioritised indications
- Establish a structured and interoperable data platform to unlock real-world-data potential in an oncology network
- Leverage the real-world-data gathered by the action to establish an AI-knowledge base and support treatment decisions for prioritized indications

Topic 4: Optimal treatment for patients with solid tumours

Expected contributions from SMEs


- Large-scale medical data management and processing
- Expertise in interoperable IT system design
- Technical interface development wrt current clinical technologies
- Advanced database and transfer security, client- and server-side encryption

Duration

60 months

Indicative budget

- In-kind contribution: EUR 11.4 million
- IMI2 JU contribution: up to EUR 10.46



Topic 5: Shortening the path to rare disease diagnosis by using new born genetic screening and digital technologies

The topic aims to:

- Assess and develop a comprehensive, strategic overview of existing converging RD resources
- Federate available RD databases into a RD metadata repository amenable to machine learning or other advanced digital tools
- Co-create a sustainable strategy for newborn genetic screening and pilot it.
- Repurpose or develop a diagnosis AI algorithm to identify early onset RD patients in electronic health records
- Repurpose or develop a broad AI RD diagnosis “symptom checker”

Topic 5: Rare disease diagnosis

Expected contributions from SMEs

- Regulatory affairs, policy and politics, health economics, HTA / pharmaco-economics, regulatory sciences, legal / IP / licensing
- Data Exchange & Building Digital Infrastructure, User experience, Data security and Data Anonymisation
- Study / Trial Operation Manager, Medical / Scientific Writing

Duration

60 months

Indicative budget

- In-kind contribution: EUR 12.6 million
- IMI2 JU contribution: up to EUR 11.94 million



Topic 6: Behavioural model of factors affecting patient adherence

The topic aims to:

- Develop a comprehensive understanding of the factors which affect patient needs and adherence
- Identify the most significant factors
- Evaluate existing models and then either create an open access behavioural model or further develop an existing model;
- Collect additional real-world data to refine the model;
- Provide tools that will enable healthcare stakeholders to cost-effectively develop and implement solutions to address patient needs and improve adherence rates.

Topic 6: Factors affecting patient adherence

Expected contributions from SMEs

- SMEs with implemented solutions (i.e. hardware and software) to measure and manage medication adherence
- Use and analysis of real-world data on treatment adherence to contribute to and validate the model, including machine learning to identify data patterns and trends;

Duration

60 months

Indicative budget

- In-kind contribution: EUR 5.95 million
- IMI2 JU contribution: up to EUR 5.95 million





SME participation in ongoing IMI projects

European Lead Factory



Screening deck of **550 000 compounds & ultra-HTS facilities** available **free** to anyone with an **innovative target to screen**.

www.europeanleadfactory.eu

NEWS

Keapstone Therapeutics, an SME that benefited from free screening at the European Lead Factory has secured a further €1,1 million investment from Parkinson's UK.

“What was attractive about the data package from ELF was that it was generated based on industrial standards”



Dr Jan Kulagowski, Drug Discovery Manager at Parkinson's UK

European Health Data & Evidence Network

- EHDEN aims to harmonise **100 million, anonymised health records** to create a federated health data network in Europe.
- Harmonisation will be carried out by certified/qualified SMEs and funded by a **EUR 16 million harmonization fund**.
- SMEs can obtain **free training & certification** which then allows them to carry out the harmonization at the data owners site.
 - <https://academy.ehden.eu/>
- Calls for SME service providers & data partners in 2020:
 - <https://www.ehden.eu/>



Thank you!

www.imi.europa.eu
@IMI_JU